Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes

What Was Tested

The paper reports a study of Exenatide, published as a randomized controlled trial.

Who Took Part

According to the abstract, 20 individuals were involved.

PubMed indexes the participants as young adults and adults, both men and women.

For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial.

After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab.

How the Study Was Run

The researchers set it up as a randomized, open-label and crossover study.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

Nothing was hidden in this open-label Exenatide study: the individuals and staff both knew the treatment.

Each person switched between Exenatide and the comparison at some point, usually with a gap in between.

Endogenous insulin production was determined by repeatedly measuring serum C-peptide.

What Was Measured

PubMed files the paper under topics including Age of Onset, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Autoimmunity, Daclizumab, Diabetes Mellitus, Type 1 and Exenatide.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Exenatide in 20 individuals.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (Diabetes care), a journal based in United States.

More context: the Exenatide compound page, all human trials.